These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34575474)

  • 1. Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro.
    Brunotte L; Zheng S; Mecate-Zambrano A; Tang J; Ludwig S; Rescher U; Schloer S
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
    Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
    Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
    Schäfer A; Martinez DR; Won JJ; Moreira FR; Brown AJ; Gully KL; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
    bioRxiv; 2021 Sep; ():. PubMed ID: 34545367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
    Cox RM; Wolf JD; Lieber CM; Sourimant J; Lin MJ; Babusis D; DuPont V; Chan J; Barrett KT; Lye D; Kalla R; Chun K; Mackman RL; Ye C; Cihlar T; Martinez-Sobrido L; Greninger AL; Bilello JP; Plemper RK
    Nat Commun; 2021 Nov; 12(1):6415. PubMed ID: 34741049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
    Schloer S; Brunotte L; Goretzko J; Mecate-Zambrano A; Korthals N; Gerke V; Ludwig S; Rescher U
    Emerg Microbes Infect; 2020 Dec; 9(1):2245-2255. PubMed ID: 32975484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs.
    Schreiber A; Ambrosy B; Planz O; Schloer S; Rescher U; Ludwig S
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.
    Deb S; Reeves AA; Hopefl R; Bejusca R
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs.
    Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
    bioRxiv; 2021 Jun; ():. PubMed ID: 32869033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.
    Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside.
    Tao S; Zandi K; Bassit L; Ong YT; Verma K; Liu P; Downs-Bowen JA; McBrayer T; LeCher JC; Kohler JJ; Tedbury PR; Kim B; Amblard F; Sarafianos SG; Schinazi RF
    Curr Res Pharmacol Drug Discov; 2021; 2():100045. PubMed ID: 34870151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An
    Xie J; Wang Z
    Acta Pharm Sin B; 2021 Jun; 11(6):1607-1616. PubMed ID: 34221871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2.
    Hahn F; Häge S; Herrmann A; Wangen C; Kicuntod J; Jungnickl D; Tillmanns J; Müller R; Fraedrich K; Überla K; Kohlhof H; Ensser A; Marschall M
    Pathogens; 2021 Aug; 10(9):. PubMed ID: 34578109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19.
    Rasmussen HB; Thomsen R; Hansen PR
    Pharmacol Res Perspect; 2022 Apr; 10(2):e00945. PubMed ID: 35396928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19.
    Tamura R; Irie K; Nakagawa A; Muroi H; Eto M; Ikesue H; Muroi N; Fukushima S; Tomii K; Hashida T
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):513-521. PubMed ID: 36798006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections.
    Zhu J; Li Y; Liang J; Mubareka S; Slutsky AS; Zhang H
    Intensive Care Res; 2022; 2(3-4):49-60. PubMed ID: 36407474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants
    Fred SM; Kuivanen S; Ugurlu H; Casarotto PC; Levanov L; Saksela K; Vapalahti O; Castrén E
    Front Pharmacol; 2021; 12():755600. PubMed ID: 35126106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
    Alvarez JC; Moine P; Etting I; Annane D; Larabi IA
    Clin Chem Lab Med; 2020 Aug; 58(9):1461-1468. PubMed ID: 32573468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
    Sun D
    AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.